High-dose alectinib for RET fusion-positive non-small cell lung cancer in the Blood First Assay Screening Trial.
Rafal DziadziuszkoNir PeledTony MokSolange PetersSantiago Ponce AixJorge Alatorre-AlexanderBrian D VicunaMargaret MaclennanVijay Bhagawati-PrasadSarah M ShaganErica SchleifmanThorsten RufMichael S MathisenShirish M GadgeelPublished in: Contemporary oncology (Poznan, Poland) (2024)
fusion-positive NSCLC, and further investigation was not conducted due to the development of selective RET inhibitors pralsetinib and selpercatinib. No new safety signals were observed, and the safety profile of alectinib was in line with previous reports at the 600 mg BID dose.